Clinical Trials Logo

Drug-resistant Tuberculosis clinical trials

View clinical trials related to Drug-resistant Tuberculosis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06224036 Recruiting - Clinical trials for Drug-resistant Tuberculosis

Clinical Study of JDB0131 Benzenesulfonate Tablets in Patients With Drug-sensitive Pulmonary Tuberculosis

Start date: October 31, 2023
Phase: Phase 2
Study type: Interventional

A randomized, open, drug controlled design of experiments was used to evaluate the early bactericidal activity, safety, tolerance and pharmacokinetic characteristics of JDB0131 benzenesulfonate tablet taken orally by drug sensitive pulmonary tuberculosis patients. Five groups are proposed to be set up in this test (JDB0131 benzenesulfonate 100mg BID, JDB0131 benzenesulfonate 200mg QD, JDB0131 benzenesulfonate 200mg BID, anti tuberculosis drug fixed dose composite dosage QD is determined according to the weight of the study participants, and delamanid 100mg BID)

NCT ID: NCT05017324 Recruiting - Clinical trials for Multidrug Resistant Tuberculosis

Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial

SMARTT
Start date: September 21, 2021
Phase: N/A
Study type: Interventional

The primary aim of this pragmatic trial is to determine the effectiveness of a Whole Genome Sequencing (WGS) Drug Sensitivity Testing (DST) strategy to guide individualised treatment of rifampicin resistant tuberculosis (RR-TB) patients. The primary objective is to determine the effectiveness of this WGS DST strategy in patients diagnosed with RR-TB. We will additionally perform an exploratory health economics evaluation of both arms, and will determine the feasibility of the WGS DST strategy.